RxDoctor Payments Data

Mohammed Sheikh, MD

Geriatric Medicine · Independence, LANPI 1144216961

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $118 and has fallen 84.5% since, to $18 in 2025.

$345in general payments, 2019–2025

Across 19 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$52
  • UCB, Inc.$48
  • Pfizer$33
  • Smith+Nephew$30
  • Gilead$29
  • Dexcom, Inc.$28
  • plus $124 from 8 others

What the payments were for

  • Food & beverage$345100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$345 in reported general payments places this provider in the 70th percentile of 40 geriatric medicine providers in Louisiana.

See all geriatric medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$38,933
Medicare patients
230
Services billed
562

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban130$81,311
OzempicSemaglutide37$63,341
JardianceEmpagliflozin46$62,183
TradjentaLinagliptin38$55,584
Spiriva HandihalerTiotropium Bromide51$37,687
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$36,343
LinzessLinaclotide36$30,445
TrulicityDulaglutide16$28,977
EntrestoSacubitril/Valsartan39$27,805
FarxigaDapagliflozin Propanediol17$26,037
JanumetSitagliptin Phos/Metformin Hcl28$21,379
MounjaroTirzepatide19$20,492
NamzaricMemantine Hcl/Donepezil Hcl12$16,849
Albuterol Sulfate HfaAlbuterol Sulfate409$13,668
Lantus SolostarInsulin Glargine,hum.Rec.Anlog108$13,234

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$33$81,311130 claims
Novo NordiskOzempic$52$63,34137 claims
AbbVieLinzess, Namzaric$11$47,29448 claims
AstraZenecaFarxiga, Symbicort$18$36,30552 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 40 geriatric medicine providers in Louisiana.

Other geriatric medicine in Independence

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →